The Jenner Institute is a research partnership between the University of Oxford and The Pirbright Institute.
The Institute focuses on the parallel development of human and vetinary vaccines against major global diseases - from early-stage research through to clinical trials.
The University of Oxford is delighted to announce that the first collaborative research projects to be agreed by the University under the Pfizer Rare Disease Consortium have been signed.
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Prof Louis Picker, Oregon Health & Science University: Breaking the Rules of CD8+ T Cell Recognition with Cytomegalovirus (CMV) Vectors, 20 Mar 13:00
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus International Journal of Cancer , 136 (6)
Identification of a novel three-domain KIR allele: KIR3DL1*087 using high-resolution molecular techniques. Tissue Antigens , 85 (2)